{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:48:41Z","timestamp":1792244921220,"version":"4.4.0"},"reference-count":14,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,27]]},"DOI":"10.20945\/2359-3997000000495","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T17:12:09Z","timestamp":1656609129000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-2925","authenticated-orcid":false,"given":"Guadalupe","family":"Vargas-Ortega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6924-2209","authenticated-orcid":false,"given":"Baldomero","family":"Gonz\u00e1lez-Virla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0373-6641","authenticated-orcid":false,"given":"Lourdes","family":"Balc\u00e1zar-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-5983","authenticated-orcid":false,"given":"Roc\u00edo","family":"Arreola-Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5290-9254","authenticated-orcid":false,"given":"Francisco Javier","family":"Benitez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1227-3201","authenticated-orcid":false,"given":"Blas L\u00f3pez","family":"F\u00e9lix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-9734","authenticated-orcid":false,"given":"Mois\u00e9s","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"key":"key20220630131145_B1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","unstructured":"1 Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017;317:516-24.","journal-title":"JAMA"},{"key":"key20220630131145_B2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.endinu.2017.05.009","article-title":"Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects","volume":"64","author":"Mercado","year":"2017","unstructured":"2 Mercado M, Melgar V, Salame L, Cuenca D. Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects. Endocrinol Diabet Nutr. 2017;64:384-95","journal-title":"Endocrinol Diabet Nutr"},{"key":"key20220630131145_B3","doi-asserted-by":"crossref","first-page":"R375","DOI":"10.1530\/ERC-20-0136","article-title":"The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)","volume":"27","author":"Yavropoulou","year":"2020","unstructured":"3 Yavropoulou MP, Tsoli M, Barkas K, Kaltsas G, Grossman A. The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs). Endocr Relat Cancer. 2020;27:R375-90. doi:10.1530\/ERC-20-0136","journal-title":"Endocr Relat Cancer"},{"key":"key20220630131145_B4","first-page":"756669","article-title":"Clinical characteristics and treatment outcome of 485 patients with non-functioning pituitary macroadenomas","author":"Vargas","year":"2015","unstructured":"4 Vargas G, Gonzalez B, Ramirez C, Ferreira A, Espinosa E, Mendoza V, Guinto G, Zepeda E, Mercado M. Clinical characteristics and treatment outcome of 485 patients with non-functioning pituitary macroadenomas. Int J Endocrinol 2015;756669","journal-title":"Int J Endocrinol"},{"issue":"2","key":"key20220630131145_B5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-15-0967","article-title":"Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up","volume":"174","author":"Ntali","year":"2016","unstructured":"5 Ntali G, Capatina C, Fazal-Sanderson V, Byrne JV, Cudlip S, Grossman AB, Wass JA, Karavitaki N. Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. Eur J Endocrinol. 2016;174(2):137-45. doi: 10.1530\/EJE-15-0967.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"key20220630131145_B6","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1210\/jc.2011-3163","article-title":"Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study","volume":"97","author":"Ram\u00edrez","year":"2012","unstructured":"6 Ram\u00edrez C, Cheng S, Vargas G, Asa SL, Ezzat S, Gonz\u00e1lez B, et al. Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab. 2012;97(5):1745-51.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20220630131145_B7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11102-010-0254-3","article-title":"Comparison of three methods for the estimation of the pituitary gland volume using magnetic resonance imaging: a stereological study","volume":"14","author":"Ertekin","year":"2011","unstructured":"7 Ertekin T, Acer N, Turgut AT, Aycan K, Oz\u00e7elik O, Turgut M. Comparison of three methods for the estimation of the pituitary gland volume using magnetic resonance imaging: a stereological study. Pituitary. 2011;14(1):31-8.","journal-title":"Pituitary"},{"issue":"3","key":"key20220630131145_B8","first-page":"351","article-title":"Current status and future directions of pharmacological therapy for acromegaly","volume":"41","author":"Mercado","year":"2016","unstructured":"8 Mercado M, Espinosa E, Ram\u00edrez C. Current status and future directions of pharmacological therapy for acromegaly. Minerva Endocrinol. 2016;41(3):351-65.","journal-title":"Minerva Endocrinol"},{"issue":"1","key":"key20220630131145_B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12345","article-title":"Efficacy of medical treatment in Cushing\u2019s disease: a systematic review","volume":"80","author":"Gadelha","year":"2014","unstructured":"9 Gadelha MR, Vieira Neto L. Efficacy of medical treatment in Cushing\u2019s disease: a systematic review. Clin Endocrinol (Oxf). 2014;80(1):1-12.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key20220630131145_B10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/2046-4053-1-33","article-title":"Treatment of hyperprolactinemia: a systematic review and meta-analysis","volume":"1","author":"Wang","year":"2012","unstructured":"10 Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW, et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012;1:33.","journal-title":"Syst Rev"},{"key":"key20220630131145_B11","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1210\/jc.2003-030859","article-title":"Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment","volume":"89","author":"Pivonello","year":"2004","unstructured":"11 Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab. 2004;89:1674-83.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20220630131145_B12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/COC.0000000000000505","article-title":"Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial","volume":"42","author":"Batista","year":"2019","unstructured":"12 Batista RL, Musolino NRC, Cescato VAS, da Silva GO, Medeiros RSS, Herkenhoff CGB, et al. Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial. Am J Clin Oncol. 2019;42:221-7.","journal-title":"Am J Clin Oncol"},{"key":"key20220630131145_B13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1015366923810","article-title":"Minor tumor shrinkage in non functioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline","volume":"4","author":"Lohmann","year":"2001","unstructured":"13 Lohmann T, Trantakis C, Biesold M, Prothmann S, Guenzel S, Schober R, et al. Minor tumor shrinkage in non functioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary. 2001;4:173-8.","journal-title":"Pituitary"},{"key":"key20220630131145_B14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/EJE-16-0206","article-title":"Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists","volume":"175","author":"Greenman","year":"2016","unstructured":"14 Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T, et al. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol. 2016;175:63-72.","journal-title":"Eur J Endocrinol"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T17:12:19Z","timestamp":1656609139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/efficacy-of-cabergoline-therapy-in-patients-with-non-functioning-pituitary-adenomas-a-single-center-clinical-experience\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":14,"alternative-id":["10.20945\/2359-3997000000495"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000495","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]}}}